Ultragenyx Pharmaceutical (RARE) Cash from Operations Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 37.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 16.64% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -7.60% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 34.32% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -7.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.89% |
| Dec 31, 2025 | -3.38% |
| Sep 30, 2025 | 1.39% |
| Jun 30, 2025 | -12.07% |
| Mar 31, 2025 | -12.20% |
| Dec 31, 2024 | -13.43% |
| Sep 30, 2024 | -3.95% |
| Jun 30, 2024 | -5.60% |
| Mar 31, 2024 | -6.18% |
| Dec 31, 2023 | -10.43% |
| Sep 30, 2023 | -23.90% |
| Jun 30, 2023 | -49.33% |
| Mar 31, 2023 | -18.13% |
| Dec 31, 2022 | -7.84% |
| Sep 30, 2022 | -2.51% |
| Jun 30, 2022 | 4.63% |
| Mar 31, 2022 | -7.06% |
| Dec 31, 2021 | 0.91% |
| Sep 30, 2021 | 4.81% |
| Jun 30, 2021 | 4.94% |
| Mar 31, 2021 | -21.21% |
| Dec 31, 2020 | 8.61% |
| Sep 30, 2020 | 0.01% |
| Jun 30, 2020 | 55.90% |
| Mar 31, 2020 | -15.84% |
| Dec 31, 2019 | -14.75% |
| Sep 30, 2019 | -45.48% |
| Jun 30, 2019 | -30.96% |
| Mar 31, 2019 | -28.73% |
| Dec 31, 2018 | -11.36% |
| Sep 30, 2018 | -31.23% |
| Jun 30, 2018 | -63.92% |
| Mar 31, 2018 | -71.76% |
| Dec 31, 2017 | -87.29% |
| Sep 30, 2017 | -77.80% |
| Jun 30, 2017 | -66.75% |
| Mar 31, 2017 | -79.28% |
| Dec 31, 2016 | -69.60% |
| Sep 30, 2016 | -62.11% |
| Jun 30, 2016 | -67.84% |
| Mar 31, 2016 | -92.51% |